ImmixBio Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors

LOS ANGELES: LOS ANGELES, Aug. 27, 2021 /PRNewswire/ -- Immix Biopharma, Inc. ("ImmixBio") today announced a clinical trial and supply agreement with BeiGene, Ltd. to evaluate the safety, tolerability and efficacy of combining IMX-110, a Tissue Specific Therapeutic™ with TME Normalization™ Technology, with BeiGene's anti-PD-1 antibody tislelizumab, for the treatment...

Click to view original post